Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Takeda Bags Big Vaccine Subsidy
by Jean-François Tremblay
August 29, 2011
| A version of this story appeared in
Volume 89, Issue 35
The Japanese government has awarded Takeda Pharmaceutical $312 million to help it invest in pandemic H5N1 flu vaccine development and manufacturing. The company is in the process of implementing in Japan a flu vaccine technology, based on Vero cells, that it licensed from Baxter International. Takeda will proceed with the construction of a commercial facility at its Hikari site, with the aim of obtaining regulatory approval for its vaccines during the 2013 fiscal year. Last year, Japan provided $47 million for the company to test Baxter’s cell-culture and purification techniques at Hikari.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X